The EU butts heads with Big Pharma to make medicines cheaper

By HEOR Staff Writer

February 2, 2023

The new EU proposal to revamp its pharmaceutical regulations. The main aim is to give people a better and more affordable access to medicines.

From what I can see, there are mixed feelings about the proposal. On one hand, consumer groups and civil society organizations are applauding the EU’s efforts to make medicines more accessible. On the other hand, the pharmaceutical industry is a bit skeptical.

So, what’s in the proposal? Well, the EU is looking to shorten the period in which pharmaceutical companies can sell their medicines without competition from 10 years to just 8 years. They’re also working towards closing the gap in access to medicines among different EU member states.

It’s interesting to see how this will all play out. What are your thoughts on the EU Pharmaceutical Regulations Proposal?

Reference url

Recent Posts

Infarmed Regulatory Activity: January 2026 Highlights and Impacts on Market Access

By João L. Carapinha

February 26, 2026

Infarmed regulatory activity in January 2026 showcased robust performance by Portugal's National Authority for Medicines and Health Products, spanning marketing authorizations, clinical trials, public reimbursement, inspections, pharmacovigilance, and enforcement. The agency processed 45 renewals...
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement

By HEOR Staff Writer

February 25, 2026

NICE Backs Ruxolitinib Cream Vitiligo Treatment Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which recommends it for non-segmental vitiligo with...
Economic Impact of Industry Clinical Trials in Europe

By João L. Carapinha

February 24, 2026

Industry clinical trials in are a vital engine of medical innovation and economic growth, with the European Economic Area (EEA) generating €35.7 billion in Gross Value Added (GVA) in 2025 from these activities. This includes €21.7 billion from direct, indirect, and induced effects, €3.6 billion f...